COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?

An alternate hypothesis: the hardly significant data suggest that in this instance the exosomes may antagonize the meager Ab effects This very slightly positive, much over ballyhooed result by The President, compared to previous studies carried out in an analogous manner and the meta‐analysis of such prior studies in seriously ill patients with

also in 165 other papers